Randi Cohen, MD
Radiation Oncology · Philadelphia, PANPI 1366570228
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,000 of the $2,810 with a category attached, or 71.2%. Davol Inc. accounts for 71.2% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2021 at $2,081 and has fallen 93.3% since, to $140 in 2025.
Across 28 payments — averaging $100.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Davol Inc.$2K
- Johnson & Johnson$341
- GE HealthCare$139
- Novartis$48
- Boehringer Ingelheim$28
- Daiichi Sankyo Inc.$27
- plus $229 from 11 others
What the payments were for
- Speaking & faculty fees$2,00071%
- Food & beverage$71125%
- Education$1004%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Davol Inc. | 1 | $2,000 |
| Johnson & Johnson(2 entities) | 11 | $341 |
| GE HealthCare | 1 | $139 |
| Novartis | 2 | $48 |
| Boehringer Ingelheim | 1 | $28 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Amgen | 1 | $26 |
| Reflexion Medical, Inc. | 1 | $25 |
| Telix Pharmaceuticals | 1 | $23 |
| Seagen Inc. | 1 | $23 |
| Novocure Inc. | 1 | $23 |
| Myriad Genetic Laboratories, Inc. | 1 | $21 |
| GSK | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Merck | 1 | $18 |
| EMD Serono, Inc. | 1 | $16 |
| Exelixis Inc. | 1 | $16 |
How this compares
$2,810 in reported general payments places this provider in the 80th percentile of 339 radiation oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 54 | $723 |
| Silodosin | 11 | $209 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Philadelphia
- Neil TaunkPhiladelphia$203K
- Wenyin ShiPhiladelphia$119K
- Kevin NeadPhiladelphia$50K
- Adam DickerPhiladelphia$46K
- Tinatin ChabrashviliPhiladelphia$39K
- Bryan PukenasPhiladelphia$36K
- Sameera KumarPhiladelphia$29K
- Joshua MeyerPhiladelphia$25K
- Abigail BermanPhiladelphia$25K
- Michelle Alonso-BasantaPhiladelphia$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.